Cytarabine is a Intravenous; Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Mylan Institutional Llc. The primary component is Cytarabine.
Product ID | 67457-454_2bef8f94-a567-49fc-b025-04e7c71b9268 |
NDC | 67457-454 |
Product Type | Human Prescription Drug |
Proprietary Name | Cytarabine |
Generic Name | Cytarabine |
Dosage Form | Injection |
Route of Administration | INTRAVENOUS; SUBCUTANEOUS |
Marketing Start Date | 2011-12-14 |
Marketing End Date | 2021-12-31 |
Marketing Category | ANDA / ANDA |
Application Number | ANDA200914 |
Labeler Name | Mylan Institutional LLC |
Substance Name | CYTARABINE |
Active Ingredient Strength | 20 mg/mL |
Pharm Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |
NDC Exclude Flag | N |
Marketing Start Date | 2011-12-14 |
Marketing End Date | 2021-12-31 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | ANDA |
Application Number | ANDA200914 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2011-12-14 |
Ingredient | Strength |
---|---|
CYTARABINE | 20 mg/mL |
SPL SET ID: | b48842dd-c5c9-484c-a3f5-cb883919b418 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
61703-303 | CYTARABINE | CYTARABINE |
61703-304 | Cytarabine | CYTARABINE |
61703-305 | Cytarabine | CYTARABINE |
61703-319 | Cytarabine | CYTARABINE |
63323-120 | Cytarabine | CYTARABINE |
67457-452 | Cytarabine | Cytarabine |
67457-454 | Cytarabine | Cytarabine |
67457-455 | cytarabine | cytarabine |
68083-337 | Cytarabine | Cytarabine |
68083-343 | Cytarabine | Cytarabine |
71288-108 | Cytarabine | Cytarabine |
71288-109 | Cytarabine | Cytarabine |
71288-168 | Cytarabine | Cytarabine |
71288-169 | Cytarabine | Cytarabine |